Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
autologous adipose-derived mesenchymal stromal cells (Royan Institute)
- Development stage
- Unknown
- Lead developer
- Royan Institute for Stem Cell Biology and Technology
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intra-ovarian Injection
01
Overview
This autologous cell therapy consists of adipose-derived mesenchymal stromal cells (ADSCs) developed by the Royan Institute for the treatment of premature ovarian failure (POF). The therapeutic process involves harvesting a patient's own adipose tissue via liposuction, isolating the stromal vascular fraction, and expanding the mesenchymal stromal cells in vitro. These cells are then delivered via direct intra-ovarian injection. The mechanism of action is centered on the cells' ability to secrete paracrine factors that create a regenerative microenvironment, promoting angiogenesis, reducing apoptosis in granulosa cells, and stimulating the renewal of folliculogenesis within the damaged ovarian tissue. Clinical evaluation has focused on safety, feasibility, and the potential to restore hormonal balance and ovarian function in women with idiopathic POF.
- Other names
- autologous adipose-derived mesenchymal stem cellsintraovarian injection of adipose derived stromal cells
Beyond the preview
Go deeper on autologous adipose-derived mesenchymal stromal cells (Royan Institute).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on autologous adipose-derived mesenchymal stromal cells (Royan Institute).